Posted inNews Articles Success achieved with the first-in-class oral anti-cancer drug, Inobrodib, by CellCentric and Sygnature Discovery. An integrated project team at Sygnature Discovery worked collaboratively… December 16, 2022Tags: anticancer, drug discovery, Inobrodib, next generation therapeutics
